miR-454-3p and miR-194-5p targeting cardiac sarcolemma ion exchange transcripts are potential noninvasive diagnostic biomarkers for childhood dilated cardiomyopathy in Egyptian patients

Alaaeldin G. Fayez1*, Nora N. Esmaiel1, Sohair M. Salem1, Engy A. Ashaat1, Sonia A. El-Saiedi2 and Mona O. El Ruby1

Abstract

Background: Childhood dilated cardiomyopathy (CDCM) is the most common cardiomyopathy in children and it is risk factor to heart failure and sudden death. Most of the different etiologic factors which have been postulated to DCM are idiopathic, and its pathogenesis remains uncertain. So it was worth investigating the potential DCM pathogenicity models to establish early noninvasive diagnosis parameters especially in CDCM patients. Beside that miRNAs in the circulatory blood are genetically considered the best option for noninvasive diagnosis; also, implementation of miRNAs as early diagnostic markers for children with DCM is urgent because those children have high risk to sudden heart death. We aimed to identify discriminator diagnostic circulatory miRNA expression levels in CDCM patients.

Results: The expression levels of miR-454-3p and miR-194-5p were found significant upregulated (p value = 0.001 and 0.018; CI 95%, respectively), while miR-875-3p was found significant downregulated (p value = 0.040; CI 95%). A receiver operating characteristic (ROC) curve analysis showed significant AUC = 1.000 and 0.798 for miR-454-3p and miR-194-5p, respectively, and the optimal discriminated diagnostic cut-points were computed by index of union (IU) method. Enrichment analysis for the potential targeted mature mRNAs by miR-454-3p and miR-194-5p pointed that Ca, Na and K ions homeostasis in cardiac sarcolemma consider potential CDCM pathogenicity model.

Conclusions: miR-454-3p and miR-194-5p are highly influencing noninvasive biomarkers for CDCM, and further circulatory miRNAs-implicated studies are highly recommended.

Keywords: Childhood dilated cardiomyopathy, Noninvasive diagnostic biomarkers, miRNAs, Cardiac sarcolemma, Gene ontology analysis

Background

Younger adults and children are most frequent affected individuals by dilated cardiomyopathy (DCM), and patients with DCM are characterized by left ventricular or biventricular dilation and depressed systolic function without others abnormal loading conditions such as valve abnormalities, coronary artery disease (CAD) and hypertension [1, 2].
Idiopathic DCM is considered to be familial in 20 to 35% of cases, and international registry data indicate that DCM is the most common reason for heart failure and cardiac transplantation in pediatric [3, 4].

Remodeling of myocardial cells is continuous process by transduction of intercellular signals and activation of the transcription and transmission pathways, and DCM has been considered outcome of several pathological pathways [5].

MicroRNAs (miRNAs, miR) are a class of functional single-stranded noncoding RNA. Cytoplasmic miRNAs consider as gene expression regulators by modifying transcription or translational through targeting mainly the 3′ untranslated region (3′UTR) of mature miRNAs, and abnormal gene expression was addressed in various genetic disorders including cardiogenesis abnormalities, cardiac hypertrophy and electrical conduction impairment [6–12].

miRNAs studies in DCM revealed dysregulated miRNAs in cardiomyocyte, and also, bioinformatic analysis revealed that the downregulation of key pro-survival miRNAs promoted apoptotic signaling and heart decompensation [13, 14]. Few studies addressed plasma miRNAs profiles in DCM, so identify unique signature in miRNA expression profiles in DCM may lead to identify new early diagnostic noninvasive biomarkers as well as new therapeutic targets. More than 50 relevant genes have been identified in DCM, including in the genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and calcium-handling proteins [15].

Circulating miRNAs would be best biomarker choices for early diagnosis of DCM, because difficulties of tissue sampling in children. According to what given above and lack of noninvasive early diagnosis biomarkers to DCM patients create a need for novel approaches to identify pathological mechanisms and support clinical decision-making, we aimed to characterize the profile of distinct plasma miRNAs expression in DCM and analyze their target genes network using target gene ontology analysis. We assessed the difference of the studied miRNAs between DCM patients and the corresponding controls; also, sensitivity, specificity and cut-point values of miRNAs expression were computed.

Reasons of targeting of the Egyptian DCM patients in the current research were (i) what was recently reported that genetic makeup of cardiomyopathy differs from ethnic to other [14]. (ii) It was found that miRNAs have differentiated profile in diseases between African and European descendants, which could be responsible for differences among those populations in susceptibility to diseases, drug sensitiveness, and biomarker diagnostics [16, 17].

**Methods**

**Patients:** A total of 37 CDCM patients and 37 non-cardiac anomalies healthy controls whose age ranged from 9 months to 18 years old were recruited from the Excellence Center of Medical Research, Clinical Genetics Department, CHD Clinic and pediatric department, Cairo university.

**Clinical investigations:** Full clinical examination of cases and control groups were done for each case with special emphasis on heart and cardiovascular system. Family history of any similarly affected person in the family and consanguinity were reported. Others possible DCM causes were excluded such as coronary artery disease (CAD) which investigated with coronary angiography and hypertensive heart disease.

**Blood sampling:** For diagnosed DCM cases and healthy individuals, blood samples had been taken into a sterile vacutainer tube with anti-coagulant factor (pot. EDTA) after the agreement signature on the consent form the children's parents or guardians.

**Blood processing and storage:** All of the blood samples were centrifuged at 3000 rpm for 15 min to collect the plasma. Then, the plasma was aliquoted in the RNase-free microfuge tubes and store at −80 centigrade.

**RNA extraction and RT-PCR:** Total plasma miRNAs were isolated using Direct-zol™ mRNA MiniPrep (Zymo Research) according to manufacturer’s protocol. Each RNA sample was quantified with a spectrophotometer (NanoDrop 1000, Thermo Scientific, Wilmington, Delaware). 20 ng of the isolated miRNAs were converted to complementary DNA (cDNA) by miScript II RT Kit (Qiagen). qRT-PCR reactions were conducted in 96-well plates with 120 ng/ul of the cDNA and miScript SYBR Green PCR Kit (Qiagen) using ROCH 480II lightcycler instrument. Quantitative real-time polymerase chain reactions will be performed in duplicate for all samples. miRNAs PCR primers will be provided upon request.

**qRT-PCR data analysis:** The data were analyzed using the relative fold change (FC) by ∆∆Ct equation and transformed log2FC values. Relative gene expression level was calculated by $2^{-\Delta\Delta C_t}$ equation, and miRNA expression levels were normalized to a nonendogenous synthetic miRNA miR-16-2.

**Target genes analysis:** To better understand the biological function of the significant dysregulated miRNAs, their putative target genes were predicted under confidence interval 95% using TargetScan [18], miRDB [19], MiRTarBase 9.0 [20] and miRWALK [21] databases; to gain deep insight into the biological functions of the differential miRNAs and target genes, the pathways of target genes will be analyzed by KEGG [22] database and protein–protein interaction (PPI) enrichment p value was computed by STRING tool [23].
Table 1. Patients and control characterization

| Group   | n  | Age (years)* mean ± SD | Gender (%) | Consanguinity (%) |
|---------|----|------------------------|------------|-------------------|
| CDCM    | 37 | 9.5 ± 2.5              | Male: 55   | +ve (76%)          |
|         |    |                        | Female: 45 | −ve (24%)          |
| Control | 37 | 8 ± 3                  | Male: 47   | NA                |
|         |    |                        | Female: 53 |                   |

*No statistically significant difference was found between CDCM and control groups for ages, p value = 0.089

Statistical analysis: Values are expressed as mean ±SD or median according to skewness and kurtosis values, and outliers’ values were excluded. Student's two-sided t test was used for mean miRNAs expression comparison. Receiver operating characteristic (ROC) curves were analyzed to assess specificity and sensitivity of each single plasma miRNA. The optimal diagnostic cut-off of the significant miRNA was assessed by index of union (IU). $p < 0.05$ value considered significant. The statistical analysis was done by PASW statistics [24] (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago).

Results

Clinical characteristics of patients: A total of 37 CDCM patients were enrolled in this study as diagnosed by the Canadian Cardiovascular Society guidelines, beside 37 age-matched non-cardiac anomalies healthy as controls. The clinical characteristics of patients are shown in Table 1.

Both miR-454-3p and miR-194-5p were significant upregulated and miR-875-3p was significant downregulated in CDCM patients: To identify miRNAs that are differentially expressed in CDCM and control, we performed real-time PCR with duplicate expression reactions to five selected miRNAs that are miR-518-3p, miR-618, miR-875-3p, miR-454-3p, and miR-194-5p from CDCM patients and controls. By applying a criterion of fold change (FC) to assess the differential miRNAs expression ratio between CDCM and control groups, it was found that fold expression change of miR-454-3p and miR-194-5p was significantly higher in CDCM patients than the control subjects. On contrast, miR-875-3p was significantly lower in CDCM patients than the control subjects as shown in Fig. 1. There was a significant correlation between CDCM occurrence and each of miR-454-3p, miR-194-5p and miR-875-3p; therefore, these miRNAs could be useful as potential diagnostic parameters to CDCM patients. Both miR-518-3p and miR-618 showed insignificant fold expression change difference between CDCM and control groups.

Diagnostic value assessment of miRNAs for CDCM; both miR-194-5p and miR-454-3p have significant discriminative cut-point values: To discriminate between the CDCM patients and the healthy controls, the receiver operating characteristic (ROC) curves were plotted for every single miRNA log2FC values. The areas under the curves (AUCs) were 0.798 and 1.000 for mir-194-5p and 454-3p, respectively. The measured optimal cut-points for them were calculated using index of union (IU) method, where 0.065 and 0.130 were the optimal discriminator boarder value for mir-194-5p and 454-3p respectively discovering the CDCM patients. These results are suggesting that these circulating miRNAs may be useful for CDCM detection and as noninvasive early diagnosis predictors as shown in Fig. 2.

Kyoto encyclopedia of genes and genomes (KEGG) pathways analyses: To predicted putative target genes of the differentially expressed miRNAs, analysis according to miRWalk tool, including TargetScan, mirDB and MirTarBase tools, was used to classify and annotate both miR-194-5p and miR-454-3p according to two KEGG pathways that are (i) cardiac muscle contraction (hsa04620) and (ii) DCM (hsa05414) over three genome regions, 3'UTR, 5'UTR and CDS as shown in Table 2. The predicted target genes are shown in Tables 3 and 4. It is worth mentioning that 3'UTR region of the targeted TGFB2 gene was found as common targeted gene between miR-194-5p and miR-454-3p with differentially binding energy $– 23.6 \text{and} – 18.3$, respectively.

To detect the relationship between overall targeted genes by miR-194-5p and miR-454-3p, protein–protein interaction (PPI) enrichment was computed by STRING tool; there are significant PPI enrichment network found as shown in Fig. 3.

Differential PPI enrichment network was done by intersection classification of the targeted proteins across three classifiers that are (i) strength (log10 [observed/expected]), (ii) false detective rate (FDR) and (iii) number of the targeted proteins as shown in Table 5 and Fig. 4a, b, c. The intersection classification showed that miR-194-5p and miR-454-3p might cause CDCM via impairment of calcium, potassium and sodium homeostasis through plasma membrane of a cardiac muscle fiber cell (sarcolemma) as shown in Fig. 4d.

Discussion

In the present study, 5 circulating miRNA biomarkers were selected from the CDCM-relevant literature to assess them as diagnostic biomarkers which can use as non-invasive early diagnosis. Notably that studies that conducted on plasma or serum miRNAs were rare. Plasma miRNAs were extracted to determine its relative expression levels by qRT-PCR in 37 CDCM patients against
The main findings of this study can be summarized as follows: (i) high positive consanguinity was observed, (ii) human miR-194-5p and miR-454-3p upregulation is potential noninvasive biomarkers for CDCM patients; (iii) ion exchange and cardiac electric conduction through cardiac sarcolemma are potential affected cellular components resulted from miR-194-5p and miR-454-3p overexpression and lead to CDCM pathogenicity; (iv) according to PPI enrichment network and GO analysis, there are 13 targeted genes may be affected by mir-194-5p and mir-454-3p overexpression, and they commonly were ATP1A1, ATP1A4, ATP1B3, CACNA2D1, CACNA1C and CACNB2 genes.

Many different etiologic factors were described to cause myocardial damage in DCM [25]. According to cardiomyopathies-relevant Egyptian studies, positive consanguinity could be risk factors in the cardiomyopathies etiology, where Darwish et al. [26] reported a first study to uncovering the genetic background of idiopathic primary hypertrophic cardiomyopathy in 24 Egyptian patients with 62.5% positive consanguinity; they pointed the high burden of consanguinity in Egyptian pediatric hypertrophic cardiomyopathy might associate with particular genetic background. Mehaney et al. [27] pointed that 53% of the studies dilated cardiomyopathy patients showed positive consanguinity, and the authors suggested that high burden of consanguinity might lead to novel genes or variants underlie pediatric cardiomyopathy in Egyptian DCM patients.

miRNAs consider as key players in idiopathic dilated cardiomyopathy, where Bioinformatic analysis revealed that the downregulation of key pro-survival miRNAs promoted apoptotic signaling and heart decompensation [28, 29].
In 2008, Sucharov et al. [30] analyzed the miRNA expression profile by microarray in tissue samples from idiopathic DCM and ischemic DCM patients. The authors identified a profile of miRNAs deregulated in both phenotypes that were miR-100 and miR-195 over-expression and miR-92 and miR-133b downexpression. Zhou et al. [31] pointed that expression levels of miR-208b was upregulated in myocardium samples. Shen et al. [32] mentioned that miR-146a could be a useful protective agent against sunitinib-induced cardiac dysfunction.

In plasma miRNAs profiling in idiopathic DCM, Coskun et al. [25] pointed that miR-618, miR-875-3p, and miR-194 were found decreased, while expression levels

![Fig. 2 Receiver operating characteristic (ROC) curve of circulating mir-194-5p and 454-3p for the diagnosis DCM]

### Table 2

miRNA-target genes analysis according to the relevant KEGG pathways (miRWalk analysis)

| Targeted gene regions | 3′UTR | 5′UTR | CDS |
|-----------------------|-------|-------|-----|
| **(I) Cardiac muscle contraction (hsa04260)** | | | |
| miR-454-3p            | +     | −     | +   |
| miR-194-5p            | +     | −     | +   |
| **(II) Dilated cardiomyopathy DCM (hsa05414)** | | | |
| miR-454-3p            | +     | −     | +   |
| miR-194-5p            | +     | −     | +   |

Under score ≥ 0.95

### Table 3

Predicted targeted genes for miR-454-3p (based on MANE transcript)

| Gene    | MANE transcript | Binding probability | Binding energy | AU rich region fraction | Positions | KEGG pathways                        |
|---------|-----------------|---------------------|----------------|-------------------------|-----------|-------------------------------------|
| CACNB2  | NM_201590       | 0.953846154         | − 20           | 0.75                    | 3′UTR     | Cardiac muscle contraction (hsa04260) |
|         | NM_201596       | 0.953846154         | − 20           | 0.75                    | 3′UTR     |                                     |
| ATP1A4  |                 |                     | − 19.6         | 0.485                   | CDS       | DCM (hsa05414)                      |
| CACNB2  | NM_201590       | 0.953846154         | − 20           | 0.75                    | 3′UTR     |                                     |
|         | NM_201596       | 0.953846154         | − 20           | 0.75                    | 3′UTR     |                                     |
| TGF2    | NM_003238       | 1                   | − 18.3         | 0.529                   | 3′UTR     |                                     |
| ITGB6   | NM_000888       | 1                   | − 19.8         | 0.5                     | CDS       |                                     |
| ITGA2B  | NM_000419       | 1                   | − 19.1         | 0.471                   | CDS       |                                     |

Common target gene in the used KEGG pathways

CACNB2

It means matched annotated transcripts from refseq (NCBI) and gencode |Ensemble;EMBL-EBI)
### Table 4  Predicted targeted genes for has-mir-194-5p (based on MANE transcript)

| Gene      | MANE Transcript | Binding probability | Binding energy | AU rich region fraction | Positions | KEEG pathways        |
|-----------|-----------------|---------------------|----------------|-------------------------|-----------|----------------------|
| CACNA2D1  | NM_000722       | 1                   | 20.5           | 0.588                   | 3′UTR     | Cardiac muscle       |
|           |                 |                     |                |                         |           | contraction (hsa04260) |
| CACNA1C   | NM_000719       | 0.991452991         | 22.1           | 0.456                   | 3′UTR     |                      |
| ATP1B3    | NM_001679       | 1                   | 17.6           | 0.515                   | CDS       |                      |
| ATP1A1    | NM_000701       | 1                   | 21.9           | 0.5                     | CDS       |                      |
| RYR2      | NM_001035       | 1                   | 20.5           | 0.5                     | CDS       |                      |
| CACNA2D1  | NM_000722       | 1                   | 20.5           | 0.588                   | 3′UTR     |                      |
|           |                 |                     |                |                         |           | DCM (hsa05414)       |
| CACNA1C   | NM_000719       | 0.991452991         | 22.1           | 0.456                   | 3′UTR     |                      |
|           |                 |                     |                |                         |           |                      |
| TGFβ2     | NM_003238       | 1                   | 23.6           | 0.529                   | 3′UTR     |                      |
| DAG1      | NM_004393       | 1                   | 19.3           | 0.441                   | 3′UTR     |                      |
| TTN       | NM_001267550    | 1                   | 22.8           | 0.515                   | CDS       |                      |
| ITGA2     | NM_002203       | 1                   | 18.3           | 0.691                   | CDS       |                      |
| RYR2      | NM_001035       | 1                   | 20.5           | 0.5                     | CDS       |                      |

Common target genes in the used KEEG pathways
CACNA2D1, CACNA1C, RYR2

It means matched annotated transcripts from refseq (NCBI) and gencode (Ensemble;EMBL-EBI)

---

**Fig. 3** PPI enrichment network for the whole target genes including interaction score on edges lines. On the right column, proteins by red highlighted refer to cardiac muscle contraction pathway relevant targets and by blue highlighted refer to DCM pathway relevant targets. PPI enrichment p value of miR-454-3p = 0.181, PPI enrichment p value of miR-194-5p = 6.09e-06
of miR-518f and miR-454 were found increased in DCM patients to consider that these miRNAs as potential diagnostic biomarkers, and these results are agreed with what were pointed in the current research except miR-194 expression which may due to different sample size or clinical traits spectrum. However, Steer and Subramanian [33] pointed that miR-875-3p expression level was similar in adult heart failure patients to those in healthy controls. This inconsistency regarding miR-875-3p expression level may due to different sample size, clinical traits spectrum, and different etiology background of which have been demonstrated to cause DCM. As far as myopallidin gene was reported to harbor DCM-relevant variants, and this gene is targeted by miR-875-3p [34], and this may be support our resulted concerning miR-875-3p downregulation in children with DCM.

From a given above, implementation of miRNAs in early diagnosis is urgent for children with DCM, where there are high risk factor to sudden heart death and also that the circulating miRNAs in the plasma is considered the first option for diagnosis because it is noninvasive tool [35]. According to our knowledge, study of plasma miRNAs in Egyptian CDCM was not studied yet, so the current study might be first one in Egyptian CDCM patients.
qRT-PCR assay, in the current study, showed that miRNA alterations were well correlated with the CDCM patients, where both miR-194-5p and miR-454-3p have positive relationships with CDCM, and on contrast, miR-875-3p has negative relationship. Also, PPI enrichment network and GO analysis showed that there are 13 targeted genes could be affected by miR-194-5p and miR-454-3p, out of them 6 target genes, ATP1A1, ATP1A4, ATP1B3, CACNA2D1, CACNA1C and CACNB2, shared in CDCM pathogenicity as consequences of miR-194-5p and miR-454-3p overexpression. Consequently, overexpression pattern of miR-194-5p and miR-454-3p might lead to downexpression and translational repression of ATP1A1, ATP1A4, ATP1B3, CACNA2D1, CACNA1C and CACNB2. Therefore, what are the potential biological role of deregulated ATP1A1, ATP1A4, ATP1B3, CACNA2D1, CACNA1C and CACNB2 in CDCM pathogenicity?

From our GO analysis, CACNA1C and CACNB2 involved in voltage-dependent calcium ion change. Molina-Navarro et al. [36] found that both CACNB2 and CACNA1C as cardiac ion channel genes were significantly downregulated in LV biopsies of DCM patients against normal heart tissue.

Our miRNAs-targets gene analysis concluded that coding sequence of MANE transcript (NM_000701) for ATP1A1 gene and coding sequence of MANE transcript (NM_001035) for RYR2 gene are targeted by miR-194-5p with high binding probability and binding energy −21.9 and −20.9, respectively. Guo et al. [37] found that mRNA levels of ATP1A1 were significantly higher (p value = p < 0.05) in the pediatric and adult DCM group than the control group. Stanczyk et al. [38] revealed experimentally Ca2+ homeostasis impairment consider pathogenic mechanism contributing to the development of DCM, HCM and/or arrhythmogenicity.

isolated cardiomyocytes from neonatal rats were isolated by Li et al. [39] to explore role of dysregulated miRNAs in the initiation and progression of myocardial ischemia–reperfusion (MI/R) in a calcium-dependent manner; they found that downregulation of miR-202-5p led to Trpv2 upregulation inhibiting Ca2+ overload in cardiomyocytes. Belevych et al. (2011), Xu et al. (2012), Curcio et al. (2013), Liao et al. (2016) revealed experimentally that miRNA-1 drives arrhythmogenesis by altering ion channels and proteins associated with the heart's electrical activity in cardiac diseases [40–43]. Also, Wiedmann et al. [44] aimed to study differential expression of selected miRNA in atrial tissue samples obtained from patients with sinus rhythm, paroxysmal AF, or permanent/chronic AF, and they found that miR-25, miR-21, miR-34a, miR-23a, miR-124, miR-1, and miR-29b upregulation as well as miR-9 and miR-485 downregulation were associated with TASK-1 potassium channel in patients with atrial cardiomyopathy. The above results conclude the disturbance of cardiac ion channel proteins resulting from dysregulated miRNAs may be one of cardiac diseases pathogenesis.

According to the current study, Ca, Na and K homeostasis impairment might be potential pathogenicity effect to cause CDCM. Feng (1992) showed that erythrocyte membrane Na-pump and Ca-pump were remarkably lower in DCM than those in the controls [45], Plank et al. [46] found 3.6-fold reduction of sarco(endo)plasmic reticulum Ca2+ -ATPase (SERCA) in cardiomyocytes, El-Battrawy et al. [47] found significant reduction of systolic and diastolic intracellular Ca2+ concentrations was detected in DCM cardiomyocytes, but potassium concentration was similar in DCM and control cardiomyocytes, and Ednie et al. [48] pointed that altered glycosylation contributes to DCM through changes in Na, and K, activity that impact conduction Ca2+ handling and contraction.

**Table 5** GO analysis for whole targeted genes (n = 13) by miR-194-5p and miR-454-3p using STRING tool

| GO                        | FDR* |
|---------------------------|------|
| Cellular components (CC)  |      |
| Sarcolemma                | 2.11e-0.6 |
| T-tubule                  | 0.00052 |
| Ca channel complex        | 0.00058 |
| Molecular function (MF)   |      |
| Alpha actinin binding     | 0.0014 |
| Sod–pot exchange          | 0.0064 |
| Biological process (BP)   |      |
| Cell communication by electric coupling involved in cardiac contraction | 4.19e-05 |
| Ca ion transport          | 0.00069 |
| Relevant pathway prioritization |      |
| KEG pathway               |      |
| DCM                       | 1.4e-10 |
| HCM                       | 1.4e-10 |
| Arrhythmogenic RV cardiomyopathy | 8.98e-09 |
| Cardiac muscle contraction | 1.29e-08 |
| Reactome pathway          |      |
| Muscle contraction        | 9.56e-05 |
| Cardiac conduction        | 0.0011 |
| Wiki pathway              |      |
| Arrhythmogenic RV cardiomyopathy | 9.13e-08 |
| Ca regulation in cardiac cell | 0.0214 |

*FDR; False Detection Rate
Conclusions

Finally, we concluded that both miR-194-5p and miR-454-3p were significantly upregulated in plasma of the studied CDCM targeting 5 potential MANE transcripts involved in Ca, Na and K homeostasis in cardiac sarcolemma according to the current research limits.

Abbreviations

CDCM: Childhood dilated cardiomyopathy; DCM: Dilated cardiomyopathy; miRNA: Micro-Ribonucleic acid; ROC: Receiver operating characteristic; AUC: Area under curve; IU: Index of union; CAD: Coronary artery disease; 3'UTR: 3' Untranslated region; 5'UTR: 5' Untranslated region; CDS: CoDon sequence; CHD: Congenital heart defect; KEGG: Kyoto encyclopedia of genes and genomes; PPI: Protein–protein interaction; FDR: False detective rate; MANE: Matched annotated transcripts between NCBI and ensemble; GO: Gene ontology.

Acknowledgements

The authors gratefully acknowledge the Science, Technology and Innovation Funding Authority (STDF) to fund this research work, also thanks for all participants and their parents, plus STDF and NRC staffs whose managed this research financially.

Author contributions

All authors revised the current research. AF was a lone contributor in idea conceptualization, results interpretation, computational work and writing, SS carried partially out the relative expression level and primer design of some primers, NE carried partially out the relative expression level and collect the whole data, EA performed clinical evaluation and journals selection, and ME and SE were major clinical supervisors. All authors read and approved the final manuscript.

Funding

This work was granted and funded by The Science, Technology and Innovation Funding Authority (STDF) under project ID, 34823.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The agreement signature on the consent form the children's parents or guardian was taken. The study protocol was ethically approved by medical research ethics committee (MREC) at national research centre (NRC) under decision no. 20177.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Human Genetics and Genome Research Institute, National Research Centre, Dokki, Egypt.
2Division of Pediatric Cardiology, Faculty of Medicine, Cairo University, Giza, Egypt.

Received: 23 February 2022 Accepted: 22 August 2022 Published online: 08 September 2022

References

1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cechi F, Charron P et al (2007) Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 29:270–276
2. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M et al (2016) Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37:1850–1858
3. Mahon NG, Murphy RT, MacRae CA (2005) Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. ACC Curr J Rev 14:31
4. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ et al (2010) The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin 6:401–413
5. Zhang Y, Kanter EM, Yamada KA (2010) Remodeling of cardiac fibroblasts following myocardial infarction results in increased gap junction intercellular communication. Cardiovasc Pathol 19:e233–240
6. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM et al (2011) Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 124:175–184
7. Thum T, Galuppo P, Kneitz S, Fedler J, Van Laake L, Mummery C et al (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. J Mol Cell Cardiol 42:5154
8. Adachi T, Nakanshi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y et al (2010) Plasma microrna-499 as a biomarker of acute myocardial infarction. Clin Chem 56:1183–1185
9. Goren Y, Kushnir M, Zafir B, Tabak S, Lewis BS, Amir O (2012) Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 14:147–154
10. Seto AC, van Rooij E (2012) Circulating microRNAs to identify human heart failure. J Heart Fail 14:118–119
11. Pasquinelli AE (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13:271–282
12. Kalozoumi G, Yacoub M, Sanoudou D (2014) MicroRNAs in heart failure: small molecules with major impact. Global Cardiol Sci Pract 2014:30
13. Isserlin R, Merico D, Wang D, Vuckovic D, Bousette N, Gramolini AO et al (2015) Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy. Mol Med Rep 10:161–168
14. McNally EM, Golbus JR, Puckelwartz MJ (2013) Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 123:19–26
15. Rawlings-Goss RA, Campbell MC, Tishkoff SA (2014) Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 7:1–3
16. McGeary SE, Lin KS, Shi CY, Pham TM, Risaria N, Kelley GM et al (2019) The biochemical basis of microRNA targeting efficacy. Sci 366:22–24
17. Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1):D127–D131
18. Heegaard NHH, West-Nørager M, Tanassi JT, Houen G, Nedergaard L, Hagdall C et al (2012) Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. PLoS ONE 7:e30997
19. Rawlings-Goss RA, Campbell MC, Tishkoff SA (2014) Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 7:1–3
20. Geary SE, Lin KS, Shi CY, Pham TM, Risaria N, Kelley GM et al (2019) The biochemical basis of microRNA targeting efficacy. Sci 366:22–24
21. Styczynski, C; De La Torre C; Farre E; Goret N (2018) miRNAwalk: an online resource for prediction of microRNA binding sites. PLoS ONE 13:e0206239
22. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M (2020) KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 48(D1):D543–551
23. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J et al (2009) STRING 8—a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37:D412–416
24. https://www.ibm.com/products/spss-statistics. Accessed from 15 Jan 2022
25. Coşkun EM, Kervancıoğlu M, Öztuzcu S, Yılmaz Coşkun F, Ergün S, Başpınar O et al (2015) Plasma microRNA profiling of children with idiopathic dilated cardiomyopathy. Biomark 21:56–61
26. Darwish RK, Haghighi A, Seliem ZS, El-Saiedi SA, Radwan NH, El-Gayar DF et al (2020) Genetic study of pediatric hypertrophic cardiomyopathy in Egypt. Cardiol Young 30(12):1910–1916
27. Mehany DA, Haghighi A, Embaby AK, Zeyada RA, Darwish RK, Elfeel NS et al (2021) Molecular analysis of dilated and left ventricular noncompaction cardiomyopathies in Egyptian children. Cardiol Young 32(2):295–300
28. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nat 469:336–342
29. Beermann J, Piccoli M-T, Viereck J, Thum T (2016) Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev 96:1297–1325
30. Sucharov C, Bristow MR, Port JD (2008) miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 45:185–192
31. Zhou Q, Schütter S, Backes D, Brüner E, Hahn JK, Ionesi E et al (2017) Inhibition of miR-208b improves cardiac function in trim-based dilated cardiomyopathy. Int J Cardiol 230:634–641
32. Shen L, Li C, Zhang H, Qiu S, Fu T, Xu Y (2019) Downregulation of miR-145a contributes to cardiac dysfunction induced by the tyrosine kinase inhibitor sunitinib. Front in Pharmacol 10:1–13
33. Steer CJ, Subramanian S (2012) Circulating microRNAs as biomarkers: a new frontier in diagnostics. Liver Transpl 18:265–269
34. Meyer T, Ruppert V, Ackermann S et al (2013) Novel mutations in the sarcomeric protein myopalladin in patients with dilated cardiomyopathy. Eur J Hum Genet 21:294–300
35. Takahashi J, Iwahashi H (2018) For novel disease diagnostic markers in Blood RNA. J Med Diagn Methods 07:1–3
36. Molina-Navarro MM, Roselló-Lletí E, Ortega A, Tarróñ E, Otero M, Martínez-Dolz L et al (2013) Differential gene expression of cardiac ion channels in human dilated cardiomyopathy. PLoS ONE 8:e79792
37. Guo Q, Liu J, Zhu P, Liu Y, Dong N, Shi J et al (2019) Evaluation of drug-related receptors in children with dilated cardiomyopathy. Front Pediatr 7:20–23
38. Stanczyk PJ, Seidel M, White J, Viero C, George CH, Zissimopoulos S et al (2018) Association of cardiac myosin-binding protein-C with the ryanodine receptor channel–putative retrograde regulation? J Cell Sci 131:jcs210443
39. Li Y, Li Q, Zhang Q, Guan X, Xue Y, Li S et al (2019) miR-202-5p protects rats against myocardial ischemia reperfusion injury by downregulating the expression of Tp63 to attenuate the Ca2+ overload in cardiomyocytes. J Cell Biochem 120(8):13680–13693
40. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM et al (2011) MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS ONE 2011(6):e28324
41. Xu HF, Ding YJ, Shen YW, Xue AM, Xu HM, Luo CL et al (2012) MicroRNA-1 represses Cx43 expression in viral myocarditis. Mol Cell Biochem 362:141–148
42. Curcio A, Torella D, Iaconetti C, Pasceri E, Sabatino J, Sorrentino S et al (2013) MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS ONE 8:e70158
43. Liao C, Gui Y, Guo Y, Xu D (2016) The regulatory function of microRNA-1 in arrhythmias. Mol Biost 12:328–333
44. Wiedmann F, Kraft M, Kallenberger S, Buescher A, Paasche A, Blochberger PL et al (2022) MicroRNAs regulate TASK-1 and are linked to myocardial dilatation in atrial fibrillation. J Am Heart Assoc 11(7):e023472
45. Feng HS (1992) Correlation of intra-erythrocytic Na, K, Ca, Mg contents and ATPase activity with dilated cardiomyopathy. Chung Hua I Hsueh Tsa Chih Taipei 72:547–549
46. Plank DM, Yatani A, Ruth S, Witt S, Glascock B, Lalli MJ et al (2003) Calcium dynamics in the failing heart: restoration by β-adrenergic receptor blockade. Am J Physiol-Heart Circ Physiol 285:305–315
47. El-Battrawy I, Zhao Z, Lan H, Li X, Yücel G, Lang S et al (2018) Ion channel dysfunctions in dilated cardiomyopathy in Limb-Girdle muscular dystrophy. Circ Genomic Preci Med 11:1–3
48. Ednie AR, Deng W, Yip K-P, Bennett ES (2018) Reduced myocyte complex N-glycosylation causes dilated cardiomyopathy. FASEB J 33:1248–1261

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article